Caribou Biosciences (CRBU) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus.
Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of 2025.
Pending confirmation of its human leukocyte antigen matching strategy, Caribou said it expects to launch a phase 3 trial for CB-010 in H2 2025.
Meanwhile, the company also expects to present dose escalation data from its cancer drug CB-011 in relapsed or refractory multiple myeloma in H1 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.